Here's a summary of the attached file, structured as requested: **Financial Highlights:** Q1 FY26 saw robust growth: standalone revenue up 29.6%, consolidated 21.7%. EBITDA surged 50.4% standalone and 45.3% consolidated.

Profit After Tax (PAT) jumped 113.3% standalone and 97.1% consolidated, with improved margins across the board.

ROCE and ROE also significantly increased.

(Note: Prigiv's losses reduced consolidated profit). **Strategic Initiatives & Growth Drivers:** Phase 2 of the speciality aroma chemical project is progressing.

Capacity augmentation (Phase 1 partly done, impacting Q2 FY26 onwards; fully by Q4 FY26 for FY27 growth) is key.

Operational excellence initiatives are enhancing margins and capital returns. **Business Developments:** A proposed amalgamation of Privi Fine Sciences and Privi Biotechnology with Privi Speciality Chemicals aims to unlock synergies, boost efficiencies, and unify the structure for scalable growth. **Market Position & Competitive Advantage:** Strong demand across all products reinforces the company's position as a trusted partner.

Privi achieved EcoVadis Platinum for ESG, ranking top 1% globally.

Advantages include high R&D, sticky customer relationships, and high industry entry barriers. **Investor Implications:** Solid Q1 financials, strategic consolidation, and capacity expansion signal positive growth potential.

Operational efficiencies and a strong market position could support sustained profitability for investors.